Atara Biotherapeutics (ATRA) Receivables (2020 - 2026)

Atara Biotherapeutics (ATRA) has reported Receivables for 7 consecutive years, with $318000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Receivables changed N/A year-over-year to $318000.0; the trailing twelve-month figure through Jun 2026 stood at $318000.0 (changed N/A YoY), and the FY2025 full-year result was $1.3 million, down 15.45% from the prior year.
• Receivables fell to $318000.0 in Q2 2026 per ATRA's latest filing, from $1.3 million in the prior quarter.
• Across five years, Receivables topped out at $40.2 million in Q4 2022 and bottomed at $163000.0 in Q3 2023.
• Historically, Receivables has averaged $8.1 million across 5 years, with a median of $1.3 million in 2024.
• The widest YoY moves for Receivables: up 8926.2% in 2024, down 95.65% in 2024.
• Over 5 years, Receivables stood at $40.2 million in 2022, then fell by 15.2% to $34.1 million in 2023, then tumbled by 95.65% to $1.5 million in 2024, then decreased by 15.45% to $1.3 million in 2025, then slumped by 74.62% to $318000.0 in 2026.
• According to Business Quant data, Receivables over the past three periods registered $318000.0, $1.3 million, and $1.9 million for Q2 2026, Q4 2025, and Q3 2025 respectively.